EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision :Clinical trial success for new cancer drug for patients with same faulty gene as Angelina Jolie

count down to zero-time

Clinical trial success for new cancer drug for patients with same faulty gene as Angelina Jolie

A new cancer drug for patients with the same faulty gene as actress Angelina Jolie has shown ‘impressive responses’ in a clinical trial, researchers have said.

The potential drug, called BMN 673, targets DNA repair in cancer cells and is designed to attack tumours that have been left vulnerable by genetic mutations.

BRCA genes were brought into the public consciousness last month after Jolie, 37, revealed she underwent a double mastectomy when doctors told her that her faulty gene – BRCA1 – meant she had an 87 per cent risk of developing breast cancer and a 50 per cent risk of ovarian cancer.

Faulty gene: Angelina Jolie arriving for the world premiere of World War Z, at the Empire Leicester Square, LondonFaulty gene: Angelina Jolie arriving for the world premiere of World War Z, at the Empire Leicester Square, London. Last month she revealed she underwent a double mastectomy

Scientists studying BMN…

View original post 415 more words

Advertisements

One thought on “EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision :Clinical trial success for new cancer drug for patients with same faulty gene as Angelina Jolie

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s